Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Biocure Technology Inc C.CURE

Alternate Symbol(s):  BICTF

Healthcare Biotechnology
Biocure Technology Inc. is a biopharmaceutical company. The Company is engaged in development and commercialization of various biopharmaceutical technologies relating to uses of recombinant and ranibizumab. The Company is comprised of scientists specializing in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. In... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (CSE:CURE)

Biocure Technology Inc. Enters into Exclusive Letter Agreement to Acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction

Newsfile September 18, 2023

Canadian Investment Regulatory Organization Trading Halt - CURE

Canada NewsWire September 14, 2023

Biocure Corporate Update

Newsfile March 25, 2022

Biocure Corporate Update and Financing

Newsfile December 2, 2021

Biocure Technology Inc. Announces Focus on its own CAR T-cell Therapy Targeting Chronic Lymphocytic Leukemia ("CLL") and Solid Tumor Cancers and Intent to Apply for Patents

Newsfile August 30, 2021

BioCure Technology Inc. Lists on the Frankfurt Stock Exchange and Completion of Issuer Sponsored Research Report

Newsfile August 3, 2021

BioCure Technology Inc. (CSE:CURE) provides corporate updates

John Ballem  July 22, 2021

BioCure Technology Inc. Announces New President, Appointment of Capital Markets Advisor and Grant of Stock Options

Newsfile July 22, 2021

BioCure Technology Inc. Announces Closing of Financing

Newsfile July 14, 2021
View More News ››

Opinion & Analysis (CSE:CURE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (CSE:CURE)

update and Intent to Apply for Patents

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2021) - BioCure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (FSE: 1WH) ("...
Betteryear2 - August 30, 2021

Great News but nobody is buying.

Sounds very promising to treat cancer. Is there anyone who can shed more light on this discovery. This could be huge but why nobody is...
sailor1986 - October 16, 2018

Great News under radar

https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aCURE-2670717&symbol=CURE&region=C The trial results demonstrated a complete...
rocman01 - October 16, 2018

New Bio-Pharmaceutical Company on the CSE

RTO of Gravis Energy is now a new Korean Bio-Pharmaceutical Company on the CSE. Do your own DD.
GMon - December 7, 2017
View more Bullboard ››

Good Natured Products Inc.

Good Natured Products Inc.

good natured Products Inc. offers an assortment of plant-based products made all, or in part, from the maximum possible ...
View More »